Nissay Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Nissay Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,027	Closed	-$281K	–	749
2019 Q3	$281K	Buy	1,027 +60	+6%	+$22K	0.01%	709
2019 Q2	$516K	Buy	967 +9	+0.9%	+$4.51K	0.01%	659
2019 Q1	$483K	Buy	958 +49	+5%	+$29K	0.01%	650
2018 Q4	$448K	Sell	909 -658	-42%	-$397K	0.01%	634
2018 Q3	$1.43M	Buy	1,567 +718	+85%	+$613K	0.04%	385
2018 Q2	$622K	Buy	+849	New	+$979K	0.02%	591

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Nissay Asset Management's NKTR Position: Q4 2019 in Review

Nissay Asset Management sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 1,027 shares — an estimated $281K sold.

Nissay Asset Management first reported a position in NKTR in Q2 2018 and held it in 6 quarters. The position peaked at $1.43M in Q3 2018. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

Nissay Asset Management reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
Nissay Asset Management sold 1,027 Nektar Therapeutics shares in Q4 2019, an estimated $281K.
Nissay Asset Management first reported a position in Nektar Therapeutics in Q2 2018 and held it in 6 quarters.
Nissay Asset Management's Nektar Therapeutics position peaked at $1.43M in Q3 2018.
281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Nissay Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.